Post Marketing Study of Anti-Pseudomonas IgY in Prevention of Recurrence of Pseudomonas Aeruginosa Infections in Cystic Fibrosis (CF) Patients
Phase of Trial: Phase I/II
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Anti pseudomonas aeruginosa IgY (Primary)
- Indications Bacterial infections; Cystic fibrosis
- Focus Therapeutic Use
- Sponsors IMMUNSYSTEM
- 31 Aug 2016 Status changed from active, no longer recruiting to completed.
- 03 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov.
- 03 Sep 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2018as reported by ClinicalTrials.gov.